{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:37:32Z","timestamp":1790750252518,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.vaccine.2006.05.093","type":"journal-article","created":{"date-parts":[[2006,6,14]],"date-time":"2006-06-14T13:17:20Z","timestamp":1150291040000},"page":"2716-2722","source":"Crossref","is-referenced-by-count":33,"title":["Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan"],"prefix":"10.1016","volume":"25","author":[{"given":"Roberta Olmo","family":"Pinheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Fonseca","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert Leonel","family":"de Matos Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando Augusto Agrellos","family":"Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Antunes","family":"de Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira Maria","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Coutinho Furtado","family":"de Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartira","family":"Rossi-Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.05.093_bib1","unstructured":"World Health Organization. Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2001. The world health report. Geneva: WHO; 2002. p. 192\u201397."},{"issue":"9496","key":"10.1016\/j.vaccine.2006.05.093_bib2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vaccine.2006.05.093_bib3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pt.2005.08.026","article-title":"Chemotherapy of trypanosomiases and leishmaniasis","volume":"21","author":"Croft","year":"2005","journal-title":"Trends Parasitol"},{"issue":"9","key":"10.1016\/j.vaccine.2006.05.093_bib4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1086\/344312","article-title":"Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission","volume":"186","author":"Courtenay","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.05.093_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","article-title":"Second generation vaccines against leishmaniasis","volume":"21","author":"Coler","year":"2005","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0264-410X(98)00338-7","article-title":"Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis","volume":"17","author":"De Luca","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.05.093_bib7","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/ije\/15.4.572","article-title":"Controlled field trials of a vaccine against New World cutaneous leishmaniasis","volume":"15","author":"Antunes","year":"1986","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib8","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.vaccine.2003.06.002","article-title":"Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis","volume":"22","author":"Armijos","year":"2004","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2006.05.093_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trstmh.2005.04.002","article-title":"Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia","volume":"99","author":"Velez","year":"2005","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2006.05.093_bib10","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.163.8.4481","article-title":"Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis","volume":"163","author":"Kenney","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.micinf.2005.04.016","article-title":"TGF-\u03b2-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with L. amazonensis antigens","volume":"7","author":"Pinheiro","year":"2005","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2006.05.093_bib12","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/IAI.72.2.988-995.2004","article-title":"Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis","volume":"72","author":"Qi","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.05.093_bib13","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2006.05.093_bib14","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1016\/S0264-410X(03)00427-4","article-title":"Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB\/c and C57Bl\/6 mice against cutaneous leishmaniasis","volume":"21","author":"Pinto","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.05.093_bib15","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/IAI.72.8.4521-4527.2004","article-title":"Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK","volume":"72","author":"Pinto","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.05.093_bib16","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.4049\/jimmunol.171.7.3711","article-title":"Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity","volume":"171","author":"Buxbaum","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib17","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1128\/IAI.55.12.3142-3148.1987","article-title":"The cellular immune-response to a purified antigen from Leishmania mexicana subsp amazonensis enhances the size of the leishmanial lesion on susceptible mice","volume":"55","author":"Rodrigues","year":"1987","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.05.093_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-3024.1986.tb01037.x","article-title":"The glycoconjugate derived from a Leishmania major receptor for macrophages is a suppressogenic, disease-promoting antigen in murine cutaneous leishmaniasis","volume":"8","author":"Mitchell","year":"1986","journal-title":"Parasite Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.05.093_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1471-4922(01)01895-5","article-title":"Is lipophosphoglycan a virulence factor? A surprising diversity between Leishmania species","volume":"17","author":"Turco","year":"2001","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib20","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.1016\/S0021-9258(19)50502-6","article-title":"Structure of Leishmania mexicana lipophosphoglycan","volume":"267","author":"Ilg","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2006.05.093_bib21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.0105-2896.2004.00190.x","article-title":"Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniasis or the visceral disease?","volume":"201","author":"McMahon-Pratt","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2006.05.093_bib22","first-page":"74","article-title":"Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo","volume":"94","author":"Rossi-Bergmann","year":"1999","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.vaccine.2006.05.093_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0014-4894(03)00098-5","article-title":"Characterization of the species- and stage-specificity of two monoclonal antibodies against Leishmania amazonensis","volume":"103","author":"Chaves","year":"2003","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijpara.2005.03.004","article-title":"The 3A1-La monoclonal antibody reveals key features of Leishmania (L.) amazonensis metacyclic promastigotes and inhibits procyclics attachment to the sand fly midgut","volume":"35","author":"Pinto-da-Silva","year":"2005","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/glycob\/7.5.687","article-title":"Leishmania adleri, a lizard parasite, expresses structurally similar glycoinositolphospholipids to mammalian Leishmania","volume":"7","author":"Previato","year":"1997","journal-title":"Glycobiology"},{"issue":"11","key":"10.1016\/j.vaccine.2006.05.093_bib26","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1128\/IAI.62.11.4893-4899.1994","article-title":"The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation","volume":"62","author":"Tolson","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.05.093_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.0105-2896.2004.00185.x","article-title":"Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice","volume":"201","author":"Sacks","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2006.05.093_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/eji.1830240403","article-title":"T helper type 1 development of na\u00efve CD4+ T cells requires the coordinate action of interleukin-12 and IFN-\u03b3 and is inhibited by TGF-\u03b2","volume":"24","author":"Schmitt","year":"1994","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib29","first-page":"22","article-title":"Enhanced CD1 expression by activated human respiratory tract dendritic cells in atopic asthma: a role for lipid antigen in allergen tolerance?","volume":"116","author":"McCarthy","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2006.05.093_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1439","article-title":"NALT-versus Peyer's-patch-mediated mucosal immunity","volume":"4","author":"Kiyono","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4102\/ojvr.v70i4.290","article-title":"Leishmania donovani-derived lipophosphoglycan plus BCG induces a Th1 type immune response but does not protect Syrian golden hamsters (Mesocricetus auratus) and BALB\/c mice against Leishmania donovani","volume":"70","author":"Tonui","year":"2003","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2006.05.093_bib32","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1128\/IAI.57.11.3349-3356.1989","article-title":"Evidence for T cell recognition in mice of a purified lipophosphoglycan from Leishmania major","volume":"57","author":"Moll","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.05.093_bib33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0952-7915(95)80112-X","article-title":"Mouse NK1+ T cells","volume":"7","author":"Bendelac","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib34","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.4049\/jimmunol.162.12.6955","article-title":"Anti-CD1 monoclonal antibody treatment reverses the production patterns of TGF-\u03b22 and Th1 cytokines and ameliorates listeriosis in mice","volume":"162","author":"Szala","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2006.05.093_bib35","first-page":"A1015","article-title":"Immunosuppressive network connecting innate immunity involving IL-10 and gamma delta T cells with acquired immunity mediated by TGF-\u03b2-producing T cells in anti-B16 immunity","volume":"14","author":"Seo","year":"2000","journal-title":"FASEB J"},{"key":"10.1016\/j.vaccine.2006.05.093_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1165\/rcmb.2002-0230OC","article-title":"Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes","volume":"30","author":"Jahnsen","year":"2004","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06006864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06006864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T18:35:09Z","timestamp":1683484509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06006864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0264410X06006864"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.05.093","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}